Vismodegib in the treatment of basal cell carcinoma: Indications for clinical practice

Piergiacomo Calzavara Pinton, Lisa Licitra, Katia Peris, Armando Santoro, Paolo Antonio Ascierto

Research output: Contribution to journalArticlepeer-review


Basal cell carcinoma (BCC) is a frequent skin cancer which can cause substantial morbidity due to its location on the face, its frequency of relapse and its capacity to invade local tissues. The primary treatment of BCC usually involves surgery or radiotherapy. In patients who have exhausted surgical and radiotherapy options or with metastatic BCC, guidelines recommend the use of the Hedgehog pathway inhibitor vismodegib. This molecule is indicated for the treatment of adults with metastatic BCC, or with locally advanced BCC which has recurred following surgery or who are not eligible to surgery or radiation. This paper aims to provide suggestions on the optimal management of BCC patients treated with vismodegib in clinical practice, according to the large experience gained by a group of Italian dermatologists and oncologists. In particular, the focus of this paper will be on the monitoring of patients and the management of adverse events.

Original languageEnglish
Pages (from-to)1429-1435
Number of pages7
JournalFuture Oncology
Issue number9
Publication statusPublished - May 1 2015


  • adverse events
  • basal cell carcinoma
  • clinical practice
  • vismodegib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Vismodegib in the treatment of basal cell carcinoma: Indications for clinical practice'. Together they form a unique fingerprint.

Cite this